Versant Ventures
Venture capital
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
38Deep-tech portfolio17 active
19Portfolio exitsAcquired or listed
2Raises, 12 monthsLatest: Gossamer Bio
66Co-investorsShare a portfolio company
Portfolio · 38 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Nexo Therapeutics | Biotech | Active | Mar 27, 2026 | $30.0M |
| Plexium | Biotech | Active | Aug 25, 2025 | $60.1M |
| Ikena Oncology | Biotech | Active | Jul 18, 2025 | $42.6M |
| 858 Therapeutics | Biotech | Active | Jul 11, 2024 | $65.2M |
| Imvax | Biotech | Active | Jul 30, 2020 | $151.8M |
| AllRock Bio | Biotech | Active | — | — |
| Antag Therapeutics | Biotech | Active | — | — |
| Arcus Biosciences | Biotech | Active | — | — |
| Borealis Biosciences | Biotech | Active | — | — |
| Chinook Therapeutics | Biotech | Active | — | — |
| Dayra Therapeutics | Biotech | Active | — | — |
| Dualitas | Biotech | Active | — | — |
| Gate Bioscience | Biotech | Active | — | — |
| Granite Bio | Biotech | Active | — | — |
| Helicore Biopharma | Biotech | Active | — | — |
| Navire Pharma | Biotech | Active | — | — |
| Tentarix | Biotech | Active | — | — |
| Gossamer Bio | Biotech | Public | Sep 4, 2026 | $728.1M |
| Latigo Biotherapeutics | Biotech | Public | Feb 13, 2025 | $50.0M |
| Rapt Therapeutics | Biotech | Acquired | Jan 3, 2025 | $302.5M |
| Tenax Therapeutics | Biotech | Public | Aug 23, 2024 | $141.8M |
| Kate Therapeutics | Biotech | Acquired | Aug 7, 2024 | $72.8M |
| Firefly Bio | Biotech | Acquired | Mar 26, 2024 | $40.0M |
| Zymeworks | Biotech | Public | Jan 3, 2024 | $50.0M |
| Nuvation Bio | Biotech | Public | Oct 20, 2020 | $275.3M |
| Escape Bio | Biotech | Closed | Sep 28, 2020 | $124.1M |
| Larimar Therapeutics | Biotech | Public | Jun 10, 2020 | $201.0M |
| Metacrine | Biotech | Closed | Jun 20, 2018 | $93.8M |
| Allogene Therapeutics | Biotech | Public | Apr 19, 2018 | $411.8M |
| Pionyr Immunotherapeutics | Biotech | Acquired | Apr 5, 2018 | $45.0M |
| Acelyrin | Biotech | Acquired | — | — |
| Annexon Biosciences | Biotech | Public | — | — |
| Corbus Pharmaceuticals | Biotech | Public | — | — |
| Cortendo | Biotech | Acquired | — | — |
| Praxis Precision Medicine | Biotech | Public | — | — |
| SixPeaks Bio | Biotech | Acquired | — | — |
| Surface Oncology | Biotech | Acquired | — | — |
| Turning Point Therapeutics | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#9
Portfolio exits#6
Raises, 12 months#12
Co-investors#15
Co-investors
- Cormorant Asset ManagementVenture capital3 shared
- Aisling CapitalVenture capital2 shared
- Andreessen HorowitzVenture capital2 shared
- Atlas VentureVenture capital2 shared
- Bay City CapitalVenture capital2 shared
- Boxer CapitalVenture capital2 shared
- Clarus VenturesVenture capital2 shared
- Deerfield Capital ManagementVenture capital2 shared
- ForbionVenture capital2 shared
- GVVenture capital2 shared
Sectors
- Biotech38
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.